Details for Patent: 8,030,292

Title:	Antisense antiviral compounds and methods for treating a filovirus infection
Abstract:	The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection. The compounds and methods relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds are morpholino oligonucleotides having: a) a nuclease resistant backbone, b) 15-40 nucleotide bases, and c) a targeting sequence of at least 15 bases in length that hybridizes to a target region selected from the following: i) the Ebola virus AUG start site region of VP24; ii) the Ebola virus AUG start site region of VP35; iii) the Marburg virus AUG start site region of VP24; or iv) the Marburg virus AUG start site region of NP.
Inventor(s):	Stein; David A. (Corvallis, OR), Iversen; Patrick L. (Corvallis, OR), Bavari; Sina (Frederick, MD), Weller; Dwight D. (Corvallis, OR)
Assignee:	AVI BioPharma Inc. (Corvallis, OR) U.S. Army Medical Research and Material Command (Frederick, MD)
Filing Date:	Mar 11, 2009
Application Number:	12/402,461
Claims:	1. A method of treating Marburg virus infection in a subject, comprising: administering to a subject a therapeutically effective amount of an antisense oligomer of 12-40 morpholino subunits linked by phosphorous-containing intersubunit linkages which join a morpholino nitrogen of one subunit to a 5' exocyclic carbon of an adjacent subunit, wherein at least 2 and no more than half of the total number of intersubunit linkages are positively charged at physiological pH; and comprising a targeting sequence which forms a heteroduplex with a target sequence of the AUG start-site region of a positive-strand mRNA for Marburg viral protein 24 (VP24); wherein the antisense oligomer inhibits virus production. 2. The method of claim 1, wherein the targeting sequence forms a heteroduplex with the AUG start-site region defined by SEQ ID NO:9. 3. The method of claim 2, wherein the targeting sequence is complementary to at least 12 contiguous bases of the sequence of SEQ ID NO:9. 4. The method of claim 2, wherein the oligomer has 15-25 subunits. 5. The method of claim 2, wherein the heteroduplex has a Tm of dissociation of at least 45.degree. C. 6. The method of claim 1, wherein the morpholino subunits are joined by intersubunit linkages in accordance with the structure: ##STR00003## wherein Y.sub.1.dbd.O, Z.dbd.O, Pj is a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide, and X is selected from alkyl alkoxy; thioalkoxy; --NR.sub.2, wherein each R is independently H or lower alkyl; or 1-piperazino. 7. The method of claim 1, which further includes administering to the subject a therapeutically effective amount of a second antisense oligomer having the same structure recited in claim 1, but having a targeting a sequence which forms a heteroduplex with a target sequence of the AUG start-site region of a positive-strand mRNA for Marburg viral protein NP (VPNP). 8. The method of claim 7, wherein the Marburg viral protein NP targeting sequence forms a heteroduplex with the AUG start-site region defined by SEQ ID NO:13. 9. The method of claim 7, wherein the Marburg viral protein NP targeting sequence is complementary to at least 12 contiguous bases of the sequence of SEQ ID NO:13. 10. The method of claim 1, wherein the targeting sequence spans the AUG start codon and has at least 14-15 bases that are complementary to SEQ ID NO:9. 11. The method of claim 1, wherein the targeting sequence has at least 12 contiguous bases of SEQ ID NO:57. 12. The method of claim 11, wherein the antisense oligomer has between 2-8 piperazine-containing intersubunit linkages, and at least one inosine base-pairing moiety. 13. The method of claim 9, wherein the NP targeting sequence is complementary to at least 14-15 bases that are upstream of the AUG start codon. 14. The method of claim 9, wherein the NP targeting sequence is complementary to at least 20 bases that are upstream of the AUG start codon, and wherein the oligomer targeted against NP has between 2-8 piperazine-containing intersubunit linkages, and at least one inosine base-pairing moiety. 15. The method of claim 7, wherein the oligomer targeted against VP24 and the oligomer targeted against NP are administered sequentially. 16. The method of claim 7, wherein oligomer targeted against VP24and the oligomer targeted against NP are administered concurrently.